{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=ribociclib&page=5", "query": { "intervention": "ribociclib", "page": 5 }, "page_size": 10 }, "pagination": { "page": 5, "page_size": 10, "total_count": 138, "total_pages": 14, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=ribociclib&page=6&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=ribociclib&page=4&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-17T18:27:01.484Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT05216432", "title": "First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tumors and in Combination With Endocrine Therapy +/- a CDK4/6 or CDK4 Inhibitor in Patients With Advanced Solid Tumors or Advanced Breast Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "PIK3CA Mutation", "Solid Tumor, Adult", "HER2-negative Breast Cancer", "Breast Cancer", "Metastatic Breast Cancer", "Advanced Breast Cancer", "Unresectable Solid Tumor" ], "interventions": [ { "name": "RLY-2608", "type": "DRUG" }, { "name": "Fulvestrant", "type": "DRUG" }, { "name": "Palbociclib 125mg", "type": "DRUG" }, { "name": "Ribociclib 400mg", "type": "DRUG" }, { "name": "Ribociclib 600mg", "type": "DRUG" }, { "name": "PF-07220060 100mg", "type": "DRUG" }, { "name": "PF-07220060 300 mg", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Relay Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 930, "start_date": "2021-12-08", "completion_date": "2027-04-30", "has_results": false, "last_update_posted_date": "2025-09-22", "last_synced_at": "2026-10-17T18:27:01.484Z", "location_count": 24, "location_summary": "Tucson, Arizona • San Diego, California • Denver, Colorado + 17 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "San Diego", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Orlando", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT05216432" }, { "nct_id": "NCT02780128", "title": "Next Generation Personalized Neuroblastoma Therapy", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Neuroblastoma", "Cancer" ], "interventions": [ { "name": "Biopsy", "type": "PROCEDURE" }, { "name": "Next Generation Sequencing", "type": "GENETIC" }, { "name": "Tumor Scans", "type": "PROCEDURE" }, { "name": "Bone marrow Tests", "type": "PROCEDURE" }, { "name": "Physical Exam", "type": "OTHER" }, { "name": "Eye Exam", "type": "OTHER" }, { "name": "Labs", "type": "OTHER" }, { "name": "Pregnancy Test", "type": "OTHER" }, { "name": "Interviews", "type": "BEHAVIORAL" }, { "name": "ECG", "type": "OTHER" }, { "name": "Echocardiogram", "type": "OTHER" }, { "name": "Ribociclib", "type": "DRUG" }, { "name": "Ceritinib", "type": "DRUG" } ], "intervention_types": [ "PROCEDURE", "GENETIC", "OTHER", "BEHAVIORAL", "DRUG" ], "sponsor": "Yael P Mosse", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Year", "maximum_age": "21 Years", "sex": "ALL", "summary": "1 Year to 21 Years" }, "enrollment_count": 66, "start_date": "2016-07", "completion_date": "2022-08", "has_results": false, "last_update_posted_date": "2026-03-10", "last_synced_at": "2026-10-17T18:27:01.484Z", "location_count": 1, "location_summary": "Philadelphia, Pennsylvania", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT02780128" }, { "nct_id": "NCT04862663", "title": "Capivasertib + CDK4/6i + Fulvestrant for Advanced/Metastatic HR+/HER2- Breast Cancer (CAPItello-292)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Locally Advanced (Inoperable) or Metastatic Breast Cancer" ], "interventions": [ { "name": "Capivasertib", "type": "DRUG" }, { "name": "Fulvestrant", "type": "DRUG" }, { "name": "Palbociclib", "type": "DRUG" }, { "name": "Ribociclib", "type": "DRUG" }, { "name": "Abemaciclib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "99 Years", "sex": "ALL", "summary": "18 Years to 99 Years" }, "enrollment_count": 893, "start_date": "2021-05-10", "completion_date": "2029-08-14", "has_results": false, "last_update_posted_date": "2026-08-17", "last_synced_at": "2026-10-17T18:27:01.484Z", "location_count": 40, "location_summary": "Tucson, Arizona • Fountain Valley, California • Glendale, California + 35 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Fountain Valley", "state": "California" }, { "city": "Glendale", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Napa", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04862663" }, { "nct_id": "NCT07085767", "title": "Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Breast Cancer", "Locally Advanced Breast Cancer", "Metastatic Breast Cancer", "ER Positive Breast Cancer", "HER2 Negative Breast Carcinoma" ], "interventions": [ { "name": "Palazestrant", "type": "DRUG" }, { "name": "Letrozole-matching placebo", "type": "DRUG" }, { "name": "Ribociclib", "type": "DRUG" }, { "name": "Letrozole", "type": "DRUG" }, { "name": "Palazestrant matching-placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Olema Pharmaceuticals, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1000, "start_date": "2025-11-03", "completion_date": "2032-01", "has_results": false, "last_update_posted_date": "2026-09-23", "last_synced_at": "2026-10-17T18:27:01.484Z", "location_count": 62, "location_summary": "Hot Springs, Arkansas • Beverly Hills, California • La Jolla, California + 54 more", "locations": [ { "city": "Hot Springs", "state": "Arkansas" }, { "city": "Beverly Hills", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Alamitos", "state": "California" }, { "city": "Oakland", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT07085767" }, { "nct_id": "NCT03477396", "title": "Ribociclib and Aromatase Inhibitor in Treating Older Participants With Hormone Receptor Positive Metastatic Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Estrogen Receptor and/or Progesterone Receptor Positive", "HER2/Neu Negative", "Stage IV Breast Cancer AJCC v6 and v7" ], "interventions": [ { "name": "Aromatase Inhibitor", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Pharmacokinetic Study", "type": "OTHER" }, { "name": "Questionnaire Administration", "type": "OTHER" }, { "name": "Ribociclib", "type": "DRUG" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "City of Hope Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "70 Years", "maximum_age": null, "sex": "ALL", "summary": "70 Years and older" }, "enrollment_count": 2, "start_date": "2018-06-14", "completion_date": "2023-06-05", "has_results": true, "last_update_posted_date": "2024-02-20", "last_synced_at": "2026-10-17T18:27:01.484Z", "location_count": 9, "location_summary": "Corona, California • Duarte, California • Lancaster, California + 6 more", "locations": [ { "city": "Corona", "state": "California" }, { "city": "Duarte", "state": "California" }, { "city": "Lancaster", "state": "California" }, { "city": "Mission Hills", "state": "California" }, { "city": "Rancho Cucamonga", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03477396" }, { "nct_id": "NCT02974725", "title": "A Phase Ib Study of LXH254-centric Combinations in NSCLC or Melanoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Non-Small Cell Lung Cancer", "Melanoma" ], "interventions": [ { "name": "LXH254", "type": "DRUG" }, { "name": "LTT462", "type": "DRUG" }, { "name": "Trametinib", "type": "DRUG" }, { "name": "Ribociclib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 241, "start_date": "2017-02-24", "completion_date": "2024-04-24", "has_results": false, "last_update_posted_date": "2025-04-13", "last_synced_at": "2026-10-17T18:27:01.484Z", "location_count": 6, "location_summary": "San Diego, California • San Francisco, California • Boston, Massachusetts + 3 more", "locations": [ { "city": "San Diego", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "New York", "state": "New York" }, { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT02974725" }, { "nct_id": "NCT06619704", "title": "Observational Retrospective Study to Assess the Use of Ribociclib in Patients With HR+, HER2- Metastatic Breast Cancer Treated With Chemotherapy", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Metastatic Breast Cancer" ], "interventions": [], "intervention_types": [], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": null, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 194, "start_date": "2022-08-10", "completion_date": "2023-09-27", "has_results": false, "last_update_posted_date": "2024-10-04", "last_synced_at": "2026-10-17T18:27:01.484Z", "location_count": 1, "location_summary": "East Hanover, New Jersey", "locations": [ { "city": "East Hanover", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT06619704" }, { "nct_id": "NCT03673124", "title": "Ribociclib and Letrozole Treatment in Ovarian Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Low Grade Serous Carcinoma" ], "interventions": [ { "name": "Ribociclib", "type": "DRUG" }, { "name": "Letrozole", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gynecologic Oncology Group", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 51, "start_date": "2019-05-20", "completion_date": "2026-12-31", "has_results": true, "last_update_posted_date": "2025-12-23", "last_synced_at": "2026-10-17T18:27:01.484Z", "location_count": 27, "location_summary": "San Francisco, California • Gainesville, Florida • Tampa, Florida + 19 more", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "Gainesville", "state": "Florida" }, { "city": "Tampa", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Evanston", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT03673124" }, { "nct_id": "NCT02555189", "title": "Enzalutamide With Ribociclib in Treating Patients With Metastatic Castrate-Resistant, Chemotherapy Naive Prostate Cancer That Retains Retinoblastoma Expression", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Castration-Resistant Prostate Carcinoma", "Metastatic Prostate Carcinoma", "Prostate Carcinoma Metastatic in the Bone", "Stage IV Prostate Cancer AJCC v7" ], "interventions": [ { "name": "Enzalutamide", "type": "DRUG" }, { "name": "Ribociclib", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Pharmacological Study", "type": "OTHER" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Biopsy", "type": "PROCEDURE" }, { "name": "Echocardiography", "type": "PROCEDURE" }, { "name": "Multigated Acquisition Scan", "type": "PROCEDURE" }, { "name": "Bone Scan", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "OTHER", "PROCEDURE" ], "sponsor": "Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 52, "start_date": "2015-12-01", "completion_date": "2023-09-01", "has_results": true, "last_update_posted_date": "2026-04-22", "last_synced_at": "2026-10-17T18:27:01.484Z", "location_count": 4, "location_summary": "Ann Arbor, Michigan • Buffalo, New York • New York, New York + 1 more", "locations": [ { "city": "Ann Arbor", "state": "Michigan" }, { "city": "Buffalo", "state": "New York" }, { "city": "New York", "state": "New York" }, { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT02555189" }, { "nct_id": "NCT07148505", "title": "A Study of Real-world Outcomes Among Patients Treated With Ribociclib", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Metastatic Breast Cancer" ], "interventions": [], "intervention_types": [], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 373, "start_date": "2024-04-24", "completion_date": "2024-11-07", "has_results": false, "last_update_posted_date": "2025-08-29", "last_synced_at": "2026-10-17T18:27:01.484Z", "location_count": 1, "location_summary": "East Hanover, New Jersey", "locations": [ { "city": "East Hanover", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT07148505" } ] }